MaxCyte (NASDAQ:MXCT – Get Free Report) and CryoPort (NASDAQ:CYRX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.
Institutional and Insider Ownership
68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by insiders. Comparatively, 9.5% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares MaxCyte and CryoPort’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MaxCyte | -121.16% | -20.03% | -17.14% |
| CryoPort | -20.05% | -7.13% | -4.29% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MaxCyte | $33.03 million | 3.83 | -$44.63 million | ($0.37) | -3.19 |
| CryoPort | $186.45 million | 4.09 | $78.30 million | ($0.90) | -16.80 |
CryoPort has higher revenue and earnings than MaxCyte. CryoPort is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
MaxCyte has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations for MaxCyte and CryoPort, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MaxCyte | 1 | 1 | 1 | 0 | 2.00 |
| CryoPort | 0 | 2 | 7 | 0 | 2.78 |
MaxCyte currently has a consensus price target of $5.00, suggesting a potential upside of 323.73%. CryoPort has a consensus price target of $18.00, suggesting a potential upside of 19.05%. Given MaxCyte’s higher probable upside, analysts plainly believe MaxCyte is more favorable than CryoPort.
Summary
CryoPort beats MaxCyte on 11 of the 14 factors compared between the two stocks.
About MaxCyte
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
About CryoPort
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
